Clinical Trial Update: Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial is evaluating CD5-targeted CAR-T cells for relapsed/refractory CD5-positive T-lymphoblastic lymphoma and is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-lymphoblastic Lymphoma

Drugs mentioned

• CD5 CAR-T cells (CD5-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Zhejiang University | Conditions: T-lymphoblastic Lymphoma | EARLY_Phase 1 | Status: RECRUITING